Home › SEC Filings › Current Report (8-K)
Current Report (8-K)
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| CTOR | 8-K | neutral | 5/10 | 🔒Citius Oncology reported preliminary fiscal Q4 2026 LYMPHIR unit sales of 792 units to U.S. wholesalers, up 120% from 36 | Oct 26, 2026 |
| JAZZ | 8-K | bearish | 6/10 | 🔒Jazz Pharmaceuticals filed an 8-K estimating a pre-tax charge of approximately $755 million for acquired IPR&D expense r | Oct 26, 2026 |
| XBIT | 8-K | neutral | 3/10 | XBiotech Inc. filed an 8-K announcing the appointment of Dr. Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive | Oct 26, 2026 |
| NEOG | 8-K/A | neutral | 2/10 | This 8-K/A amends the original 8-K filed on October 7, 2026, to add Item 5.02 disclosure regarding shareholder approval | Oct 26, 2026 |
| OTLC | 8-K | neutral | 2/10 | Oncotelic Therapeutics filed an 8-K to report that its Chief Business Officer presented a research framework (Partitione | Oct 26, 2026 |
| AZTR | 8-K | neutral | 4/10 | Azitra announced positive ex vivo data for its ATR-COSF cosmetic product candidate, showing up to ~50% reduction in fine | Oct 26, 2026 |
| APVO | 8-K | neutral | 4/10 | Aptevo Therapeutics announced that 10 of 47 (21%) evaluable frontline AML patients treated with mipletamig in combinatio | Oct 26, 2026 |
| ORKA | 8-K | bullish | 6/10 | Oruka Therapeutics announced positive Week 16 results from its Phase 2b EVERLAST-B trial of ORKA-001 in moderate-to-seve | Oct 26, 2026 |
| XNCR | 8-K | bullish | 6/10 | Xencor presented updated Phase 1 results for XmAb819 (ENPP3 x CD3 bispecific) in advanced ccRCC at ESMO 2026, showing a | Oct 26, 2026 |
| ABOS | 8-K | neutral | 6/10 | Acumen Pharmaceuticals reported Q3 2026 financial results with a net loss of $25.4 million ($0.35 per share), narrower t | Oct 26, 2026 |
| ZEOX | 8-K | neutral | 5/10 | Zeo ScientifiX (ZEOX) entered into a definitive strategic partnership agreement with Pluri Inc. (PLUR) to expand U.S. ma | Oct 26, 2026 |
| CLYM | 8-K | bullish | 6/10 | Climb Bio announced initial Phase 2 data from its PrisMN trial of budoprutug in primary membranous nephropathy (pMN) at | Oct 26, 2026 |
| PHAT | 8-K | bearish | 5/10 | Phathom Pharmaceuticals disclosed that the FDA has opened a public docket to solicit comments on legal and regulatory is | Oct 26, 2026 |
| EIKN | 8-K | neutral | 5/10 | Eikon Therapeutics announced updated Phase 2 data from its TeLuRide-005 trial of EIK1001 (TLR7/8 dual-agonist) in first- | Oct 26, 2026 |
| AVBP | 8-K | bullish | 6/10 | ArriVent BioPharma announced initial Phase 1 data for its CDH17-targeted ADC ARR-217 at ESMO 2026, showing a 44.8% ORR a | Oct 26, 2026 |
| IONS | 8-K | bullish | 7/10 | Ionis partner Roche announced positive Phase 3 IMAgINATION data for sefaxersen in IgA nephropathy, showing a statistical | Oct 23, 2026 |
| MGNX | 8-K | bullish | 7/10 | MacroGenics reported positive interim Phase 1 data for MGC026, a B7-H3-directed ADC, at ESMO 2026. In heavily pretreated | Oct 23, 2026 |
| CLYM | 8-K | bullish | 7/10 | Climb Bio announced additional Phase 1 data for CLYM116/MIL116, an anti-APRIL antibody for IgA nephropathy, at ASN Kidne | Oct 23, 2026 |
| EDSA | 8-K | neutral | 2/10 | Edesa Biotech filed an 8-K on October 23, 2026, reporting that its Board approved substantial increases in the annual ba | Oct 23, 2026 |
| BKHA | 8-K | neutral | 2/10 | Black Hawk Acquisition Corp deposited $150,000 into its trust account to extend the deadline for completing an initial b | Oct 23, 2026 |
| TRAW | 8-K | bearish | 7/10 | Traws Pharma entered into a Common Stock Purchase Agreement with Roth Principal Investments, LLC, allowing the company t | Oct 23, 2026 |
| MDCX | 8-K | neutral | 5/10 | Medicus Pharma received a delisting determination letter from Nasdaq on October 20, 2026, after failing to meet the $1.0 | Oct 23, 2026 |
| TCRT | 8-K | bullish | 5/10 | Alaunos Therapeutics received Nasdaq confirmation that it has regained compliance with the $2.5M minimum stockholders' e | Oct 23, 2026 |
| BIOE | 8-K | neutral | 2/10 | Bio Essence Corp. filed an 8-K reporting the election of Thea Zhang and Geoff Fellows as directors by shareholder writte | Oct 23, 2026 |
| GRDX | 8-K | neutral | 2/10 | GridAI Technologies Corp. filed an 8-K reporting the resignation of board member Manpreet Uppal effective October 19, 20 | Oct 23, 2026 |
| CPIX | 8-K | neutral | 4/10 | Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for s | Oct 23, 2026 |
| APVO | 8-K | neutral | 2/10 | Aptevo Therapeutics filed an 8-K to amend its shareholder rights plan (poison pill), extending the expiration date by on | Oct 23, 2026 |
| PHAT | 8-K | bearish | 6/10 | Phathom disclosed that BDR Pharmaceuticals has sued the FDA challenging the agency's refusal to accept an ANDA referenci | Oct 23, 2026 |
| MTEX | 8-K/A | bearish | 5/10 | Mannatech filed this 8-K/A to add the required auditor letter (Exhibit 16.1) from former auditor BDO USA, P.C., confirmi | Oct 23, 2026 |
| ACAD | 8-K | neutral | 3/10 | Acadia Pharmaceuticals filed an 8-K confirming the departure of Elizabeth H.Z. Thompson, Ph.D., Executive Vice President | Oct 23, 2026 |